Associate Director/Director, Patient Marketing
Boost your chances before you apply.
Celcuity
US
Summary
The Associate Director/Director will lead the development of the patient marketing strategy and promotional platform for the product REVTORPYK. They will collaborate across functions to ensure strategic alignment, manage promotional campaigns, and represent the voice of the patient in brand strategy.
Job Description
The Associate Director / Director, Patient Marketing will play a pivotal role in the launch of Celcuity’s first product – REVTORPYK. REVTORPYK is a novel, multi-target PI3K/AKT/mTOR (PAM) pathway inhibitor initially focused on advanced breast cancer, with the potential for additional indications. The successful candidate will develop a comprehensive, patient-centered promotional engagement strategy, lead the development of the patient marketing promotional platform, and create related tactics for patients, caregivers, advanced practice providers (APPs), and other nursing stakeholders. Additionally, this person will help represent the voice of the patient and caregiver in the development of brand strategy and commercial priorities. This is a highly visible, high-growth role that requires strong strategic thinking, superior cross-functional collaboration, and the ability to operate at all levels of a rapidly growing organization.
Responsibilities:
Essential Job Functions and Responsibilities may include but are not limited to:
- Lead the development of the patient marketing strategy for REVTORPYK, ensuring alignment to APP/nursing, patient, and caregiver needs as well as the overarching brand strategy and commercial objectives
- Lead the development of the patient promotional platform, including messaging, creative campaigns, and promotional tactics
- In collaboration with Promotional lead, develop a comprehensive APP/nursing educational platform and omnichannel approach
- In collaboration with the Multi-channel Marketing Lead, develop a comprehensive patient omnichannel strategy
- Oversee the internal prioritization and review process of patient materials, projects, and resources through the Promotional Review Committee
- Partner with commercial operations, sales, medical, and market access to ensure strategic alignment and seamless execution of tactics
- Monitor, assess, and optimize promotional campaigns using performance metrics and insights
- Collaborate with creative and media agencies to manage assigned tactics and budget responsibly. Ensure effective coordination as needed and ensure projects are completed within budget and on time
- Partner with patient advocacy to compliantly support advocacy-related and patient-facing initiatives
- Ensure compliance with regulatory and compliance/legal standards for pharmaceutical promotions.
- Represent Celcuity as a trusted partner in the oncology community
- Other duties as assigned.
Qualifications
Required:
`
- B.S./B.A. in science, business, marketing, or a related field
- 10+ years of commercial experience in the pharmaceutical/biotech industry
- 5+ years of oncology marketing experience, including direct patient marketing
- Proven track record in leading the development and implementation of successful marketing campaigns
- Product launch experience as a promotional marketer
- 2+ years Pharma sales experience, preferable in oncology
- Demonstrated cross-functional collaboration, including managing across teams and external agencies
- Knowledge of FDA regulations governing pharmaceutical promotions and compliance standards, including the Promotional Review Committee process
- Exceptional communication and presentation skills, with the ability to influence at all levels of the organization
- Entrepreneurial mindset and a track record of exploring new ways of working, driving new opportunities, and catalyzing others to build creative solutions
- Sound judgment and decision-making skills
- Solid planning and project management capabilities
Preferred:
- MBA or advanced degree in a related field
- Marketing experience in breast cancer
- Cross-functional experience in areas such as market analytics, sales, sales management, or key customer marketing
About Celcuity:
Celcuity is a commercial biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. REVTORPYK is approved to treat adults with HR+/HER2- advanced breast cancer that progressed on prior endocrine therapy in the metastatic setting.
The Phase 3 VIKTORIA-2 trial is evaluating gedatolisib in combination with palbociclib and either fulvestrant or letrozole for the first-line treatment of HR+/HER2- locally advanced or metastatic breast cancer. A Phase 1/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing.
Celcuity is an Equal-Opportunity Employer.
Celcuity is committed to fair and equitable compensation practices, and we strive to provide employees with total compensation packages that are competitive. The exact base pay offered for this role will depend on various factors, including but not limited to the candidate’s geography, qualifications, skills, and experience.
The successful candidate will be eligible for an annual performance incentive bonus and a new hire equity package. Celcuity also offers various benefits offerings, including, but not limited to, medical, dental, vision insurance, 401(k) match, PTO, and paid holidays.
Notice to Recruiters/Staffing Agencies
Recruiters and staffing agencies should not contact Celcuity through this page. All recruitment vendors (search firms, recruitment agencies, and staffing companies) are prohibited from contacting our hiring manager(s), executive team members, or employees directly.
We require that all recruiters and staffing agencies have a fully executed, formal written agreement on file. Celcuity’s receipt or acceptance of an unsolicited resume submitted by a vendor organization to this website or employee does not constitute an actual or implied contract between Celcuity and such organization and will be considered unsolicited. Celcuity will not be responsible for related fees.
Celcuity is a biotechnology company focused on developing and delivering targeted therapies for the treatment of multiple solid tumor indications. Our first FDA-approved product is REVTORPYK(TM)(gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together.
Our Phase 3 clinical trial, VIKTORIA-1, evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, for the treatment of patients with HR+/HER2- advanced breast cancer (ABC). Data from this trial is the basis for FDA approval of REVTORPYK for use in adult patients with HR+/HER2- ABC without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of the VIKTORIA-1 study were presented at ASCO 2026. Our Phase 3 clinical trial, VIKTORIA-2, is an ongoing trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib in combination with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib in combination with palbociclib and letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing.
More detailed information about Celcuity’s active clinical trials is available at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis.
Founded
2012
Company size
51-200 employees
Industry
Biotechnology
Org type
Public Company
Headquarters
Minneapolis, MN
Celcuity is a biotechnology company focused on developing and delivering targeted therapies for the treatment of multiple solid tumor indications. Our first FDA-approved product is REVTORPYK(TM)(gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together.
Our Phase 3 clinical trial, VIKTORIA-1, evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, for the treatment of patients with HR+/HER2- advanced breast cancer (ABC). Data from this trial is the basis for FDA approval of REVTORPYK for use in adult patients with HR+/HER2- ABC without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of the VIKTORIA-1 study were presented at ASCO 2026. Our Phase 3 clinical trial, VIKTORIA-2, is an ongoing trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib in combination with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib in combination with palbociclib and letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing.
More detailed information about Celcuity’s active clinical trials is available at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis.
Founded
2012
Company size
51-200 employees
Industry
Biotechnology
Org type
Public Company
Headquarters
Minneapolis, MN